Key result
Ivabradine is highlighted as a non-inferior alternative to existing heart rate-reducing medications for managing diverse cardiovascular pathologies.
Why the study?
Heart rate perturbations drive morbidity and mortality across diverse cardiovascular conditions, drawing attention to ivabradine as an alternative heart rate-reducing medication.
Ivabradine is highlighted as a non-inferior alternative to existing heart rate-reducing medications for managing various cardiovascular and systemic pathologies.
Ivabradine provides selective HR reduction option; leaves open expanded use across listed conditions pending prospective data.
Cardiac dysregulation, specifically perturbations in heart rate constitutes a pivotal factor influencing the morbidity and mortality associated with diverse pathological conditions including angina (chronic/stable), acute coronary syndrome, heart failure, renal failure, respiratory distress, chronic obstructive pulmonary disease, multiorgan dysfunction syndrome, mitral valve prolapse, and mitral stenosis. The pharmacological apparatus for heart rate control refined over decades encompasses various classes of agents each adhering to specific protocols. Among these Ivabradine has garnered attention as a non-inferior alternative to extant heart rate-reducing medications providing a subtle approach to cardiovascular therapeutics.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2024) conducted a review in Cardiovascular pathologies. Ivabradine vs. Extant heart rate-reducing medications was evaluated. Ivabradine is highlighted as a non-inferior alternative to existing heart rate-reducing medications for managing diverse cardiovascular pathologies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: